Molecular devices purchases Transfluor imaging technology.
Notably, this purchase expands Molecular Devices' consumables business and also gives it a new way to reach potential instrument customers. The acquisition includes intellectual property (IP) rights, certain third-party contracts pertaining to the IP, contracts granted for the technology as well as related biological materials and documents. Xsira was also granted a royalty-free, fully paid license.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Executive briefing: news, trends & market intelligence for instrument executives|
|Publication:||Instrument Business Outlook|
|Article Type:||Brief Article|
|Date:||Mar 15, 2005|
|Previous Article:||Smiths adds to security technology portfolio.|
|Next Article:||MWG biotech sells microarray assets.|